Fulcrum Therapeutics rises after trial data of blood disorder drug

Shares of drug developer Fulcrum Therapeutics FULC.O jump 49.4% to $13.30 premarket

Flucrum said on Sunday its experimental drug showed positive results in patients with sickle cell disease from an ongoing 20 dose cohort of an early-stage trial

Sickle cell disease is an inherited blood disorder that affects the hemoglobin in red blood cells

In a 12-patient study, the company is testing the safety and efficacy of its experimental drug, pociredir, an oral once-daily HbF inducer

FULC says every patients in the study experienced a significant rise in fetal hemoglobin (HbF) levels after treatment

Company plans to re-engage with the FDA in H1 2026

RBC Capital Markets says it remains on the sidelines, awaiting further regulatory clarity around Fulcrum Therapeutics' development plans

"We think it will be important to see... whether regulators will allow FULC to move directly into a pivotal trial or ask for an intermediate Phase II trial first" brokerage adds

As of last close, stock was up 89.4% YTD